CheckMyStock - Developed By GMS Ahimsa

WuXi Biologics (Cayman) Inc. (2269.HK)

$35.58 0.00 (0.00%)

Financial Ratios

Book Value per Share (BVPS)
N/A
Net asset value per share of common stock
Debt-to-Equity Ratio
0.23
(Financial Modeling Prep)
Measures financial leverage and company risk
Return on Invested Capital (ROIC)
12.43%
(Financial Modeling Prep)
Efficiency of capital allocation for generating returns
Price-to-Earnings Ratio (P/E)
29.90
(Financial Modeling Prep (calculated))
Shows how much investors are willing to pay per dollar of earnings

Company Information

Company Name
WuXi Biologics (Cayman) Inc.
Stock Ticker
2269.HK
Market Cap
N/A
52 Week Range
20.4-44
Price
$35.58
Dividend Yield
N/A
About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Top 10 Similar Stocks